We are live on ! Find out more

Evolus

EOLS

Market cap $504M

7.63 USD

+0.26

3.53%

At close Updated Oct 28, 4:00 PM EDT

Pre-market

After hours

7.60

-0.03

0.39%

1 day

3.53%

5 days

3.25%

1 month

-4.15%

3 months

22.67%

6 months

44.78%

Year to date

13.54%

1 year

8.38%

5 years

0%

10 years

-33.65%

About: Evolus Inc is a performance beauty company offering medical aesthetic products in the cash-pay aesthetic market. The company's commercially available products represent two product categories within medical aesthetics: injectable neurotoxins and injectable hyaluronic acid (HA) gels. Its commercial products are: Jeuveau, a proprietary 900-kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe frown lines, in adults; and Evolysse, a collection of injectable HA gels that utilizes first-generation cold technology. The line includes several products, including mid face, nasolabial folds, lips, and eyes. Geographically, the company currently has operations in the United States, Canada, Europe, and Australia.

Employees: 353

Healthcare Drug Manufacturers - Specialty & Generic

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 20%

Neutral 75%

Negative 5%

Evolus to Participate in Upcoming Investor Conferences in New York and London

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that members of its management team will participate in two upcoming investor conferences in New York and London: The Stifel Healthcare Conference, where management will participate in a fireside chat and host investor meetings on Wednesday, November 11, 2026, in New York City. The fireside chat is scheduled for 2:0.

Evolus to Participate in Upcoming Investor Conferences in New York and London

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Evolus, Inc. - EOLS

NEW YORK, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Evolus, Inc. (“Evolus” or the “Company”) (NASDAQ: EOLS). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Evolus, Inc. - EOLS

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Evolus, Inc. - EOLS

NEW YORK, Oct. 22, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Evolus, Inc. ("Evolus" or the "Company") (NASDAQ: EOLS). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Evolus, Inc. - EOLS

Evolus to Report Third Quarter Financial Results on November 4, 2026

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that it will report its third quarter 2026 financial results on Wednesday, November 4, 2026, after the U.S. financial markets close.Evolus management will host a conference call and live webcast to discuss these results at 4:30 p.m. ET that same day. A question-and-answer session will follow management's remarks.To p.

Evolus to Report Third Quarter Financial Results on November 4, 2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Evolus, Inc. - EOLS

NEW YORK, Oct. 20, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Evolus, Inc. (“Evolus” or the “Company”) (NASDAQ: EOLS). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Evolus, Inc. - EOLS

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Evolus, Inc. - EOLS

NEW YORK, Oct. 15, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Evolus, Inc. ("Evolus" or the "Company") (NASDAQ: EOLS). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Evolus, Inc. - EOLS

Evolus Expands Innovation Pipeline with Novel Injectable Hair Restoration Program

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a global performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that it has entered into an option agreement with a privately held company developing a novel, procedure-based, sustained-release injectable treatment for hair restoration.The agreement advances Evolus' business development strategy by adding a potential new category that is complementary to its existing injec.

Evolus Expands Innovation Pipeline with Novel Injectable Hair Restoration Program

EOLS Investors with $100,000 in Losses Have Opportunity to Join Evolus, Inc. Fraud Investigation with SBS Law

LOS ANGELES--(BUSINESS WIRE)---- $EOLS--EOLS Investors with $100,000 in Losses Have Opportunity to Join Evolus, Inc. Fraud Investigation with SBS Law.

EOLS Investors with $100,000 in Losses Have Opportunity to Join Evolus, Inc. Fraud Investigation with SBS Law

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Evolus, Inc. - EOLS

NEW YORK, Oct. 8, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Evolus, Inc. ("Evolus" or the "Company") (NASDAQ: EOLS). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Evolus, Inc. - EOLS

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Evolus, Inc. - EOLS

NEW YORK, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Evolus, Inc. (“Evolus” or the “Company”) (NASDAQ: EOLS). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Evolus, Inc. - EOLS

See News Rankings

Price charts implemented using Lightweight Charts™